ACAD and SLNO Related Headlines
Go Back- Baird: 'Acadia shares should come out relatively unscathed after the dust settles'
- ACAD failure eliminates a competitive threat to Soleno Therapeutics (SLNO) - Oppenheimer
- BMO Capital: 'expect ACAD shares to decline'
- Wells Fargo on Soleno Therapeutics Inc. (SLNO): 'We Think Shares Should Trade Up at Least +20% on ACAD Failure'
- Stifel on Soleno Therapeutics Inc. (SLNO): 'we remain bullish and believe Vykat is well-positioned for significant/sustained growth'
